 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...5253545556575859606162...100101» |
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jan 14, 2021
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2020 --> Jan 2021
- || letrozole / Generic mfg.
Trial completion: RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2 (clinicaltrials.gov) - Jan 14, 2021
P2, N=25, Completed, Sponsor: Nicholas Macklon
Trial completion date: Sep 2020 --> Jan 2021 Recruiting --> Completed
- || fulvestrant / Generic mfg.
Clinical, Journal: Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer. (Pubmed Central) - Jan 13, 2021
In contrast, the staining-based ER Allred score was not significantly associated with therapy response (p=0.2).The ERPAS identified a subgroup of ER-positive patients with a functionally inactive ER pathway associated with primary endocrine resistance. Results confirm the potential of measuring functional ER pathway activity to improve prediction of response and resistance to endocrine therapy.
- | letrozole / Generic mfg., megestrol / Generic mfg.
Trial completion date, Trial primary completion date: PIONEER: A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer (clinicaltrials.gov) - Jan 13, 2021
P2, N=189, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Results confirm the potential of measuring functional ER pathway activity to improve prediction of response and resistance to endocrine therapy. Trial completion date: Dec 2021 --> Nov 2022 | Trial primary completion date: Sep 2020 --> Oct 2021
- || letrozole / Generic mfg.
Clinical, Journal: The presence of dominant follicles and corpora lutea does not perturb response to controlled ovarian stimulation in random start protocols. (Pubmed Central) - Jan 12, 2021
Subgroup analyses according to the phase of the cycle at the initiation of COS, the type of malignancy, the use of letrozole and the magnitude of the ovarian response did not allow to identify any condition showing a difference in the follicular response between the active and the resting ovaries. In conclusion, follicular growth does not seem to be perturbed by the presence of a dominant follicle or a corpus luteum.
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: ADEPT: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (clinicaltrials.gov) - Jan 12, 2021
P2, N=375, Recruiting, Sponsor: Dana-Farber Cancer Institute
In conclusion, follicular growth does not seem to be perturbed by the presence of a dominant follicle or a corpus luteum. Not yet recruiting --> Recruiting
- |||| Verzenio (abemaciclib) / Eli Lilly
New P4 trial, Combination therapy, Metastases: A Study of Abemaciclib in Indian Women With Advanced Breast Cancer (clinicaltrials.gov) - Jan 12, 2021
P4, N=100, Not yet recruiting, Sponsor: Eli Lilly and Company
- | Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Trial completion date, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Jan 11, 2021
P1/2, N=42, Active, not recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Trial completion date: Oct 2020 --> Mar 2021
- | letrozole / Generic mfg., itraconazole / Generic mfg.
Preclinical, Journal: Azole pharmaceuticals induce germinal vesicle breakdown (GVBD) in preovulatory oocytes of zebrafish (Danio rerio): an in vitro study. (Pubmed Central) - Jan 9, 2021
Among azoles, letrozole induced GVBD in 73-85%, fluconazole (30-33%), itraconazole (23-33%), ketaconazole (46-53%), ornidazole (36-40%), and clotrimazole (30-33%) of oocytes. These results suggest that azole pharmaceuticals induce GVBD in fish oocytes that may be attributed to their variable degree of cytochrome P450 enzyme inhibitor activity.
- || letrozole / Generic mfg.
Clinical, Journal: The Role of Letrozole (LE) in Controlled Ovarian Stimulation (COS) in Patients at High Risk to develop Ovarian Hyper Stimulation Syndrome (OHSS). A prospective randomized controlled pilot study. (Pubmed Central) - Jan 9, 2021
In PCOS patients with extremely high AMH levels the LE co-administration to GnRH-Ant protocols results in reduced incidence of OHSS than conventional GnRH-Ant protocols. LE co-administration may prove to be highly effective in preventing OHSS, even in the women who are at high risk to these dangerous complications.
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) - Jan 8, 2021
P3, N=309, Recruiting, Sponsor: University of California, San Francisco
LE co-administration may prove to be highly effective in preventing OHSS, even in the women who are at high risk to these dangerous complications. N=144 --> 309 | Trial completion date: Nov 2020 --> Jan 2022 | Trial primary completion date: Nov 2020 --> Jan 2022
- | letrozole / Generic mfg.
Enrollment change, Trial withdrawal: LEFT: Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Jan 8, 2021
P4, N=0, Withdrawn, Sponsor: CRG UZ Brussel
N=144 --> 309 | Trial completion date: Nov 2020 --> Jan 2022 | Trial primary completion date: Nov 2020 --> Jan 2022 N=242 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment open, Trial completion date: EUROPA: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ?70 Years Early Stage Breast Cancer (clinicaltrials.gov) - Jan 7, 2021
P3, N=926, Recruiting, Sponsor: Azienda Ospedaliero-Universitaria Careggi
N=242 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Jan 2030
- | letrozole / Generic mfg.
Trial initiation date: Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) (clinicaltrials.gov) - Jan 6, 2021
P2, N=28, Not yet recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Jan 2030 Initiation date: Nov 2020 --> Mar 2021
- | Preclinical, Journal: Phytochemical profiling and ameliorative effects of Achillea cretica L. on rat model of endometriosis. (Pubmed Central) - Jan 6, 2021
Initiation date: Nov 2020 --> Mar 2021 AC aerial extract may be a favorable medicine for management of endometriosis by modulating inflammatory cytokines; however, further studies are needed for more conclusive and reliable decision about its efficacy and safety.
- | tamoxifen / Generic mfg.
Biomarker, Journal: MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. (Pubmed Central) - Jan 6, 2021
In addition, MCM3 was shown to be a predictive marker of response to endocrine treatment. Our study reveals a coordinated signaling network centered around MCM3 that limits response to endocrine therapy in ER breast cancer and identifies MCM3 as a clinically useful prognostic and predictive biomarker that allows personalized treatment of ER breast cancer patients.
- ||| letrozole / Generic mfg.
Clinical, Journal, Adverse events: Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity. (Pubmed Central) - Jan 6, 2021
To the best of our knowledge, this is the first study assessing the impact of CYP19A1 genetic variations with adjuvant letrozole treatment-associated AEs in Indian women. Genetic variations in the CYP19A1 gene is associated with letrozole-induced AEs and warrants further investigation in larger cohorts to validate this finding.
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. (Pubmed Central) - Jan 5, 2021
Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and rs9340799 were genetic predictors of AI-induced arthralgia. Significantly, rs4775936 was also a predictor of discontinuation of therapy.
- || Ibrance (palbociclib) / Pfizer
Clinical, P2 data, Journal, Combination therapy: Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). (Pubmed Central) - Jan 5, 2021
P2
Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS. Pfizer Inc (NCT00721409).
- || NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - Jan 5, 2021
P=N/A, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Pfizer Inc (NCT00721409). Trial completion date: Jan 2023 --> Aug 2022 | Trial primary completion date: Jan 2023 --> Aug 2022
- |||| amcenestrant (SAR439859) / Sanofi
Trial primary completion date, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Jan 4, 2021
P3, N=810, Recruiting, Sponsor: Sanofi
Trial completion date: Jan 2023 --> Aug 2022 | Trial primary completion date: Jan 2023 --> Aug 2022 Trial primary completion date: Jan 2024 --> May 2024
- || letrozole / Generic mfg.
Clinical, Journal: Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome. (Pubmed Central) - Jan 1, 2021
Here, we treated Sprague Dawley rats with the aromatase inhibitor, letrozole, to increase the endogenous testosterone level and to decrease the estradiol levels...Our results show that an elevated endogenous testosterone level can induce hepatic steatosis. Decreasing the endogenous testosterone level in hepatocytes may represent a new approach in the treatment of NAFLD in PCOS patients.
- || letrozole / Generic mfg.
Clinical, Journal: Effect of misoprostol with and without letrozole on induction of abortion for women with first-trimester missed abortion. (Pubmed Central) - Dec 31, 2020
Decreasing the endogenous testosterone level in hepatocytes may represent a new approach in the treatment of NAFLD in PCOS patients. Administration of misoprostol alone was found to be as effective as the administration of misoprostol plus letrozole for first-trimester missed abortion.
- ||| atirmociclib (PF-07220060) / Pfizer
Enrollment open, Combination therapy, Metastases: C4391001: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov) - Dec 30, 2020
P1, N=52, Recruiting, Sponsor: Pfizer
Administration of misoprostol alone was found to be as effective as the administration of misoprostol plus letrozole for first-trimester missed abortion. Not yet recruiting --> Recruiting
- || letrozole / Generic mfg.
Clinical, Journal: A multicenter randomized trial of personalized acupuncture, fixed acupuncture, letrozole, and placebo letrozole on live birth in infertile women with polycystic ovary syndrome. (Pubmed Central) - Dec 30, 2020
P3
This study will be the first multicenter RCT to compare the effect of personalized or fixed acupuncture with letrozole or placebo letrozole on live birth in infertile women with PCOS. The findings will inform whether personalized acupuncture therapy can be considered an alternative treatment to improve the live birth rate in infertile women with PCOS.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Evaluating rates of neutropenia with Ibrance therapy adjustments based on day 15 labs. () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3811;
The primary endpoint is the incidence of guidelines discordant dose adjustments made by prescribers based on day 15 labs. The secondary endpoints are percentage of Ibrance prescriptions filled at this institution, incidence of adverse effects (grade 3 and 4 neutropenia, nausea, vomiting, fatigue), patient outcomes (duration of therapy and disease progression) and incidence of guideline discordant dose adjustments among different regimens (Ibrance/letrozole, Ibrance/anastrazole, Ibrance/fulvestrant).
- |||| Piqray (alpelisib) / Novartis
Clinical: At a median follow-up of 15 months, the combination of alpelisib and letrozole led to a median progression-free survival of 5.7 months in patients with HER2-negative advanced breast cancer. @SABCSSanAntonio #SABCS20 @hoperugo #bcsm https://t.co/wir9PL8cik (Twitter) - Dec 25, 2020
- ||| letrozole / Generic mfg.
Clinical: super interesting #tweetorial on natural cycle vs ovulation stimulation (OS) for therapeutic donor insemination for singles or lesbian couples. bottom line: higher clinical ongoing pregnancy rate w/OS (Clomid or letrozole) but higher risk of multiples (Twitter) - Dec 24, 2020
- ||| Ibrance (palbociclib) / Pfizer
Trial completion, Combination therapy: Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer (clinicaltrials.gov) - Dec 23, 2020
P2, N=162, Completed, Sponsor: Dana-Farber Cancer Institute
The secondary endpoints are percentage of Ibrance prescriptions filled at this institution, incidence of adverse effects (grade 3 and 4 neutropenia, nausea, vomiting, fatigue), patient outcomes (duration of therapy and disease progression) and incidence of guideline discordant dose adjustments among different regimens (Ibrance/letrozole, Ibrance/anastrazole, Ibrance/fulvestrant). Active, not recruiting --> Completed
- || gedatolisib (PF-05212384) / Celcuity
Enrollment closed, Combination therapy, Metastases: B2151009: A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer (clinicaltrials.gov) - Dec 23, 2020
P1b, N=141, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: A Case of Recurrent Breast Cancer with Drug-Induced Interstitial Pneumonia Triggered by the Switch from an Original to a Generic Aromatase Inhibitor (Pubmed Central) - Dec 22, 2020
The patient's condition improved on a steroid pulse and artificial respiration; however, she died of aspiration pneumonia. We report a case of recurrent breast cancer with drug-induced interstitial pneumonia triggered by the switch from an original to a generic aromatase inhibitor.
- | letrozole / Generic mfg.
Journal: In vitro maturation with letrozole priming: Can it be a solution for patients with cancerophobia? A pilot study. (Pubmed Central) - Dec 22, 2020
Aromatase inhibitors can be used to preserve the fertility of patients with estrogen-sensitive cancers. Letrozole priming appears to be an efficient approach in patients who undergo IVM, with likely less cost than FSH priming.
- ||| medroxyprogesterone injection / Generic mfg.
Clinical, Journal, Adverse events: Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database. (Pubmed Central) - Dec 21, 2020
Furthermore, antiresorptive agents (i.e., BPs and denosumab) tended to induce MRONJ and atypical femoral fractures by affecting osteoclasts. We believe these findings will help medical personnel manage the side effects of many medications.
- | letrozole / Generic mfg.
Journal: Letrozole- a controversial drug for OHSS prevention? (Pubmed Central) - Dec 20, 2020
We believe these findings will help medical personnel manage the side effects of many medications. No abstract available
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) - Dec 19, 2020
P1, N=37, Completed, Sponsor: M.D. Anderson Cancer Center
No abstract available Active, not recruiting --> Completed | Trial completion date: Jul 2021 --> Dec 2020 | Trial primary completion date: Jul 2021 --> Dec 2020
- | letrozole / Generic mfg.
Journal: The effects of letrozole on women with endometriosis undergoing ovarian stimulation for in vitro fertilization. (Pubmed Central) - Dec 18, 2020
The mean percentage of mature oocytes was lower (69.9 ± 23.7% versus 80.2 ± 21.0%, p = .029) in patients with protocol 1. While maintaining low estrogen levels, the combination therapy with letrozole and gonadotropin produce similar oocyte and embryo yield to the conventional IVF protocol in women with endometriosis.
- ||||| Piqray (alpelisib) / Novartis
Clinical: Alpelisib and letrozole sustained efficacy in patients w/ PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer who received prior treatment w/ the combination of a CDK4/6 inhibitor and fulvestrant. @hoperugo @UCSFCancer @ASH_hematology #ASH20 https://t.co/2xYUc1L5lb (Twitter) - Dec 18, 2020
- || Clinical, Journal: Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. (Pubmed Central) - Dec 18, 2020
Pain intensity was generally greater in the CAM group. Therefore, because of the risk of non-compliance and treatment discontinuation due to the development of higher pain levels, special attention must be paid to patient education and aftercare in these patients.
- | letrozole / Generic mfg.
Preclinical, Journal, IO Biomarker: Dendrobium nobile Lindl. polysaccharides improve follicular development in PCOS rats. (Pubmed Central) - Dec 18, 2020
polysaccharides (DNLP) on ovarian follicular development in letrozole-induced PCOS rats and explored the underlying molecular mechanisms...DNLP exerted its protective effects via improving follicular development and inhibiting apoptosis of ovarian granular cells in PCOS rats. This study will provide experimental basis for the future clinical application of DNLP in the treatment of PCOS.
- | letrozole / Generic mfg.
Journal: Effects of the Fertility Drugs Clomiphene Citrate and Letrozole on Kiss-1 Expression in Hypothalamic Kiss-1-Expressing Cell Models. (Pubmed Central) - Dec 18, 2020
Letrozole-induced Kiss-1 gene expression in mHypoA-55 cells was not modulated in the presence of E2. The fertility drugs CC and letrozole modulated Kiss-1 expression in hypothalamic cell models.
- || letrozole / Generic mfg.
Clinical, Journal: Aromatase Inhibition Ameliorates Decreased LH Output Found in Obese Women. (Pubmed Central) - Dec 18, 2020
Letrozole (2.5-5 mg) was given daily to 22 women, 12 obese and 10 normal weight, for 7 days...The increase in LH pulse amplitude indicates that the AI effect is mediated at the level of the pituitary. Our results suggest that the hypogonadotropic phenotype of simple obesity is subject to modulation by interruption of estradiol negative feedback.
- | letrozole / Generic mfg.
Journal: MiRNAs expression profiling of rat ovaries displaying PCOS with insulin resistance. (Pubmed Central) - Dec 18, 2020
These results indicate that differentially expressed miRNAs in rat ovaries may be involved in the pathophysiology of insulin resistance in PCOS. Our study may be beneficial in establishing miRNAs as novel diagnostic and therapeutic biomarkers for insulin resistance in PCOS.
- || letrozole / Generic mfg.
Biomarker, Review, Journal: Predictive factors for intrauterine insemination outcomes: a review. (Pubmed Central) - Dec 17, 2020
Our study may be beneficial in establishing miRNAs as novel diagnostic and therapeutic biomarkers for insulin resistance in PCOS. Providers recommending IUI for treatment of infertility should take into account all of these factors when evaluating patients and making treatment recommendations.
- || letrozole / Generic mfg.
Clinical, Journal: Comparing the effect of clomiphene citrate and letrozole on ovulation induction in infertile women with polycystic ovary syndrome. (Pubmed Central) - Dec 17, 2020
The clinical consequence of drug use (pregnancy) in group A was better than group B (p=0.007). Although more clinical studies are needed, letrozole is recommended for women with polycystic ovaries and those resistant to clomiphene citrate.
- || PF-06804103 / Pfizer
Trial completion date, Trial primary completion date: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Dec 17, 2020
P1, N=148, Recruiting, Sponsor: Pfizer
Although more clinical studies are needed, letrozole is recommended for women with polycystic ovaries and those resistant to clomiphene citrate. Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024
- || Imlygic (talimogene laherparepvec) / Amgen
Enrollment change: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - Dec 17, 2020
P1b, N=25, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024 N=15 --> 25
- | Soltamox (tamoxifen citrate) / Jazz
Trial completion date, Trial primary completion date: The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov) - Dec 17, 2020
P2, N=30, Recruiting, Sponsor: Johns Hopkins University
N=15 --> 25 Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
- || letrozole / Generic mfg.
Clinical, Retrospective data, Journal: Predictor for supraphysiologic serum estradiol elevation on hCG triggering day of controlled ovarian stimulation using letrozole and gonadotropins in women with estrogen-dependent cancers. (Pubmed Central) - Dec 15, 2020
Patients with early monitoring serum estradiol ≥84.5 pg/mL had an odds ratio of 5.376 [95% CI, 1.613-17.913] for supraphysiologic elevation of serum estradiol compared to those with early monitoring serum estradiol below 84.5 pg/mL. In conclusion, early monitoring serum estradiol is an independent predicting factor for supraphysiologic level of serum estradiol on hCG triggering day in the COS cycles using letrozole and gonadotropins.
- | New trial, Real-world evidence, Real-world: Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast (clinicaltrials.gov) - Dec 13, 2020
P, N=1354, Active, not recruiting, Sponsor: First Hospital of China Medical University
- | sacibertinib (Hemay022) / Tianjin Hemay Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer (clinicaltrials.gov) - Dec 11, 2020
P1, N=48, Recruiting, Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd
In conclusion, early monitoring serum estradiol is an independent predicting factor for supraphysiologic level of serum estradiol on hCG triggering day in the COS cycles using letrozole and gonadotropins. Trial completion date: Jul 2019 --> Jul 2021 | Trial primary completion date: Mar 2019 --> Feb 2021